- Previous Close
135.00 - Open
134.35 - Bid 130.25 x --
- Ask 139.95 x --
- Day's Range
134.35 - 140.40 - 52 Week Range
122.00 - 230.00 - Volume
247 - Avg. Volume
4,205 - Market Cap (intraday)
825.758M - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
13.23 - EPS (TTM)
10.58 - Earnings Date Apr 10, 2025 - Apr 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Aug 1, 2019
- 1y Target Est
--
Makers Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations in India. The company offers general health therapeutic products, such as acid regulatory, anthelmintic, anti-allergic, anti-asthmatic, anti-biotic, anti-diabetics, anti-diarrhoeals, anti-emetics and anti-nauseants, anti-fungal, anti-hypertensive, antiinflammatory, analgesic, anti-spasmodic, anti-malarial, and anti-thyroid. It also provides cough and cold control, digestives, neurotonics, nutritional supplements, topical anti-biotic/anti-microbial, and other specialties drugs. The company sells its products under the Duramol, Artemak-AB, Loroquin, Nimuwin, Coffwin, and Exylin brand names. It distributes its products through agents, stockiest, doctors, and retailers. Makers Laboratories Limited was incorporated in 1984 and is based in Mumbai, India.
www.makerslabs.com121
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: MAKERSL.BO
View MorePerformance Overview: MAKERSL.BO
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MAKERSL.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MAKERSL.BO
View MoreValuation Measures
Market Cap
796.55M
Enterprise Value
788.75M
Trailing P/E
12.75
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.70
Price/Book (mrq)
1.12
Enterprise Value/Revenue
0.69
Enterprise Value/EBITDA
4.49
Financial Highlights
Profitability and Income Statement
Profit Margin
5.45%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.15B
Net Income Avi to Common (ttm)
62.5M
Diluted EPS (ttm)
10.58
Balance Sheet and Cash Flow
Total Cash (mrq)
76.81M
Total Debt/Equity (mrq)
6.88%
Levered Free Cash Flow (ttm)
--